TransMedics Group is trading 4.82% down at $72.83, with no confirmed catalyst for the October 16 move.
- No fresh company announcement explaining the move surfaced in the search.
- Stifel reiterated a Hold rating, citing long-term competition concerns; flight data pointed to third-quarter revenue above consensus, but available coverage does not establish that the note caused the decline.
- Healthcare-sector strength was reported, while major indexes were mixed.